PRI-724

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
PRI-724
Accession Number
DB15034
Type
Small Molecule
Groups
Investigational
Description

PRI-724 is under investigation in clinical trial NCT03620474 (Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis).

Structure
Thumb
Synonyms
Not Available
Categories
UNII
43Y934BBZ6
CAS number
1198780-38-9
Weight
Average: 658.652
Monoisotopic: 658.230484489
Chemical Formula
C33H35N6O7P
InChI Key
VHOZWHQPEJGPCC-AZXNYEMZSA-N
InChI
InChI=1S/C33H35N6O7P/c1-22-31-38(29(40)21-36(2)39(31)33(42)35-19-24-8-4-3-5-9-24)28(18-23-13-15-27(16-14-23)46-47(43,44)45)32(41)37(22)20-26-11-6-10-25-12-7-17-34-30(25)26/h3-17,22,28,31H,18-21H2,1-2H3,(H,35,42)(H2,43,44,45)/t22-,28-,31-/m0/s1
IUPAC Name
(4-{[(6S,9S,9aS)-1-(benzylcarbamoyl)-2,9-dimethyl-4,7-dioxo-8-[(quinolin-8-yl)methyl]-octahydro-1H-pyrazino[2,1-c][1,2,4]triazin-6-yl]methyl}phenoxy)phosphonic acid
SMILES
C[C@H]1[C@H]2N([C@@H](CC3=CC=C(OP(O)(O)=O)C=C3)C(=O)N1CC1=CC=CC3=C1N=CC=C3)C(=O)CN(C)N2C(=O)NCC1=CC=CC=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
64854018

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAdenocarcinoma of the Pancreas / Advanced Pancreatic Cancer / Pancreatic Cancer Metastatic1
1RecruitingTreatmentHepatitis C Virus-infected Cirrhosis1
1RecruitingTreatmentLiver Cirrhosis, Biliary / Primary Biliary Cholangitis1
1TerminatedTreatmentAdvanced Solid Tumors1
1, 2CompletedTreatmentChronic Myeloid Leukemia (CML) / Leukemia Acute Myeloid Leukemia (AML)1
1, 2RecruitingTreatmentHepatitis C Viral Infection / Liver Cirrhoses / Viral Hepatitis B1
2Not Yet RecruitingTreatmentColorectal Adenocarcinoma / Stage IVA Colorectal Cancer / Stage IVB Colorectal Cancer1
Not AvailableCompletedNot AvailableHepatitis C Virus-infected Cirrhosis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00634 mg/mLALOGPS
logP2.09ALOGPS
logP0.44ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)1.81ChemAxon
pKa (Strongest Basic)4.12ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area155.85 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity171.76 m3·mol-1ChemAxon
Polarizability65.6 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:44 / Updated on March 01, 2020 22:00

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates